Shandong Yanggu Huatai Chemical Co., Ltd. (300121.SZ) Bundle
Crunching the numbers behind Shandong Yanggu Huatai Chemical Co., Ltd. (300121.SZ) reveals a mix of steady top-line momentum and margin pressures that should grab any investor's attention: the company posted revenue of CNY 858.10 million in the quarter ending September 30, 2025 and a trailing twelve months revenue of CNY 3.48 billion (with a 2010-2025 CAGR of 10.25%), yet 2024 net income fell to CNY 192.13 million (down 36.86% year‑on‑year) while operating cash flow remains robust at CNY 380 million, margins are modest (net profit margin 4.8%, ROE 4.92%), and per‑employee revenue sits near CNY 1.64 million across 2,121 staff; balance‑sheet metrics show a conservative capital structure with a debt‑to‑equity of 0.16, total debt of CNY 468 million offset by cash and equivalents of CNY 546 million (net cash position), strong liquidity (current ratio 4.06, quick ratio 3.15), and manageable leverage (debt/EBITDA 1.46, interest coverage 6.10), while market valuation signals growth expectations (market cap CNY 6.06 billion, trailing P/E 41.59, forward P/E 26.26, EV/EBITDA 17.11) against a backdrop of a 13.47% one‑year share price gain and strategic growth levers-planned export increases (targeting a 15% uplift to USD 1.73 billion), CNY 210 million in R&D, product diversification efforts, and workforce development (500 additional trainings) - compelling reasons to dive deeper into revenue drivers, margin dynamics, valuation nuances and sector risks in the full analysis
Shandong Yanggu Huatai Chemical Co., Ltd. (300121.SZ) - Revenue Analysis
Shandong Yanggu Huatai Chemical Co., Ltd. reported steady top-line performance with modest quarter-to-quarter and year-over-year movements. Key headline figures and contextual metrics follow.
- Quarter ending Sept 30, 2025 revenue: CNY 858.10 million (up 1.18% vs. prior quarter)
- Trailing twelve months (TTM) revenue: CNY 3.48 billion (YoY growth: 3.37%)
- Full-year 2024 revenue: CNY 3.43 billion (down 0.69% vs. prior year)
- Revenue per employee: ~CNY 1.64 million (Total employees: 2,121)
- Market capitalization: CNY 6.06 billion; Price-to-Sales (P/S): 1.74
- Revenue CAGR since 2010: 10.25%
| Metric | Value | Notes |
|---|---|---|
| Quarterly Revenue (Q3 2025) | CNY 858.10 million | +1.18% vs. prior quarter (Q2 2025) |
| TTM Revenue | CNY 3.48 billion | YoY +3.37% |
| Annual Revenue (2024) | CNY 3.43 billion | -0.69% vs. 2023 |
| Employees | 2,121 | Revenue per employee ≈ CNY 1.64 million |
| Market Capitalization | CNY 6.06 billion | P/S = 1.74 |
| Revenue CAGR (2010-present) | 10.25% | Long-term top-line growth |
For broader corporate context and historical perspective, see: Shandong Yanggu Huatai Chemical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Shandong Yanggu Huatai Chemical Co., Ltd. (300121.SZ) - Profitability Metrics
Key profitability indicators for Shandong Yanggu Huatai Chemical Co., Ltd. (300121.SZ) illustrate a company with positive but softening earnings power in 2024, supported by strong operating cash generation.
- Net income (2024): CNY 192.13 million, down 36.86% from CNY 304.3 million in 2023.
- Diluted EPS (2024): CNY 0.47 vs. CNY 0.75 in 2023.
- Return on equity (ROE): 4.92% - moderate profitability relative to equity base.
- Net profit margin: 4.8% - indicates modest conversion of revenue into profit.
- Operating cash flow: CNY 380 million - significantly higher than net income, pointing to strong cash conversion from operations.
- Dividend payout ratio: ~45% with dividend per share of CNY 0.21.
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Net Income (CNY) | 192,130,000 | 304,300,000 | -36.86% |
| Diluted EPS (CNY) | 0.47 | 0.75 | -37.33% |
| ROE | 4.92% | - | - |
| Net Profit Margin | 4.8% | - | - |
| Operating Cash Flow (CNY) | 380,000,000 | - | - |
| Dividend per Share (CNY) | 0.21 | - | - |
| Dividend Payout Ratio | ≈45% | - | - |
Interpretation and investor considerations:
- Profitability compression: The near 37% drop in EPS and similar decline in net income highlight margin pressure or one-off impacts in 2024 that materially reduced bottom-line results.
- Cash vs. accrual earnings: Operating cash flow of CNY 380 million exceeds net income by ~CNY 187.87 million, signaling robust cash generation and potential resilience despite weaker accounting profits.
- Dividend sustainability: A ~45% payout ratio on reduced earnings still yields CNY 0.21/share; the cash-rich operating position supports this payout but investors should monitor future earnings recovery to sustain dividends.
- ROE and margin context: ROE of 4.92% and net margin of 4.8% suggest moderate capital efficiency and slim per-revenue profitability - suitable for conservative income-focused investors but less attractive for aggressive growth investors without signs of margin recovery.
- Key monitoring items: trajectory of operating margins, working capital trends (given strong cash flow), capex needs, and whether the 2024 decline reflects cyclical pressures or structural issues.
For strategic background and corporate direction that could impact future profitability, see: Mission Statement, Vision, & Core Values (2026) of Shandong Yanggu Huatai Chemical Co., Ltd.
Shandong Yanggu Huatai Chemical Co., Ltd. (300121.SZ) - Debt vs. Equity Structure
Shandong Yanggu Huatai Chemical Co., Ltd. (300121.SZ) presents a conservative capital structure characterized by low leverage, solid liquidity and adequate coverage of interest obligations. Key metrics point to a balance-sheet profile that prioritizes cash reserves over debt financing, supporting operational flexibility and resilience to short-term shocks.- Debt-to-equity ratio: 0.16 - reflects limited reliance on borrowed capital relative to shareholders' equity.
- Current ratio: 4.06 - indicates strong short-term liquidity and ability to meet near-term liabilities.
- Interest coverage ratio: 6.10 - demonstrates sufficient operating earnings to cover interest expenses.
- Enterprise value: CNY 6.03 billion vs. Market capitalization: CNY 6.06 billion - EV closely tracks market value, signaling modest net debt impact on valuation.
- Total debt: CNY 468 million; Cash and equivalents: CNY 546 million - net cash position (cash > debt).
- Debt-to-EBITDA: 1.46 - low financial leverage, implying manageable debt service relative to operating profit.
| Metric | Value | Implication |
|---|---|---|
| Debt-to-Equity Ratio | 0.16 | Conservative capital structure |
| Current Ratio | 4.06 | Strong short-term liquidity |
| Interest Coverage Ratio | 6.10 | Adequate ability to service interest |
| Enterprise Value (EV) | CNY 6.03 billion | Valuation close to market cap |
| Market Capitalization | CNY 6.06 billion | Equity market value |
| Total Debt | CNY 468 million | Modest absolute indebtedness |
| Cash & Equivalents | CNY 546 million | Exceeds total debt - net cash |
| Net Debt | CNY -78 million | Net cash position (cash minus debt) |
| Debt-to-EBITDA | 1.46 | Low leverage vs. earnings |
Shandong Yanggu Huatai Chemical Co., Ltd. (300121.SZ) - Liquidity and Solvency
- Quick ratio: 3.15 - ample liquid assets to cover near-term liabilities without relying on inventory conversion.
- Current ratio: 4.06 - strong short-term financial health with current assets far exceeding current liabilities.
- Net cash position: cash and equivalents exceed total debt - the company carries more cash than outstanding borrowings.
- Operating cash flow: CNY 380 million - materially higher than reported net income, indicating strong cash conversion from operations.
- Interest coverage ratio: 6.10 - operating earnings comfortably cover interest expenses.
- Debt-to-EBITDA: 1.46 - low financial leverage consistent with manageable debt levels.
| Metric | Value | Interpretation |
|---|---|---|
| Quick Ratio | 3.15 | High liquidity excluding inventory |
| Current Ratio | 4.06 | Strong short-term solvency |
| Cash & Equivalents vs. Total Debt | Net cash position | Cash > Total debt - lower financial risk |
| Operating Cash Flow | CNY 380 million | Healthy cash generation; exceeds net income |
| Interest Coverage Ratio | 6.10 | Comfortable ability to meet interest obligations |
| Debt-to-EBITDA | 1.46 | Low leverage; room to withstand earnings volatility |
- Practical investor takeaway: liquidity metrics (quick ratio 3.15, current ratio 4.06) and net cash status reduce short-term default risk and provide flexibility for capital allocation.
- Operational strength: CNY 380M operating cash flow exceeding net income signals quality of earnings and resilience in cash generation.
- Leverage profile: interest coverage of 6.10 and debt/EBITDA of 1.46 imply conservative borrowing and capacity to service debt under stress.
Shandong Yanggu Huatai Chemical Co., Ltd. (300121.SZ) - Valuation Analysis
Shandong Yanggu Huatai Chemical Co., Ltd. (300121.SZ) shows valuation multiples that imply the market is pricing in above-average growth expectations while assigning a premium to its assets and sales. Key headline figures capture both current market sentiment and forward-looking expectations.- Trailing P/E: 41.59 - indicates the market is paying CNY 41.59 for each CNY 1 of trailing earnings, implying rich historical earnings multiple.
- Forward P/E: 26.26 - the market expects earnings to improve, lowering the forward multiple versus trailing.
- P/S: 2.00 - equity valued at twice annual revenue, signaling moderate revenue premium.
- P/B: 1.93 - market values equity at nearly 1.93× book value, reflecting asset-quality or ROE expectations.
- EV/EBITDA: 17.11 - valuation relative to operating cash generation sits in mid-to-high range for the sector.
- Market Capitalization: CNY 6.06 billion; Enterprise Value: CNY 6.03 billion - near parity suggests limited net debt or balanced capital structure.
- 1‑Year Price Change: +13.47% - positive share-price performance consistent with constructive sentiment.
| Metric | Value | Implication |
|---|---|---|
| Trailing P/E | 41.59 | High historical earnings multiple |
| Forward P/E | 26.26 | Market expects earnings growth |
| P/S | 2.00 | Shares trade at 2× revenue |
| P/B | 1.93 | Nearly double book value |
| EV/EBITDA | 17.11 | Moderate-to-elevated enterprise valuation |
| Market Capitalization | CNY 6.06 billion | Equity market value |
| Enterprise Value | CNY 6.03 billion | Firm value including debt/ cash adjustments |
| 1‑Year Stock Price Change | +13.47% | Positive investor sentiment |
- Combination of a high trailing P/E and materially lower forward P/E signals that investors expect meaningful near-term improvement in profitability or one-time factors affecting historical earnings.
- Close parity between market cap and enterprise value suggests net debt is minimal or offset by cash - an important input when comparing EV/EBITDA across peers.
- Relative multiples (P/S and P/B near 2×) imply a consistent premium on both sales and assets, so growth and return-on-equity drivers will be key to justify valuation.
Shandong Yanggu Huatai Chemical Co., Ltd. (300121.SZ) - Risk Factors
Shandong Yanggu Huatai Chemical Co., Ltd. operates in a capital- and commodity-intensive segment of the chemical industry; investors should weigh several company-specific and macro drivers that could materially affect financial performance and valuation.
- Highly competitive chemical manufacturing sector: domestic and international peers pressure pricing and margins, especially for commodity chemical products.
- Raw material price volatility: feedstock such as methanol, naphtha, natural gas and intermediates expose margins to input-cost swings.
- Environmental and regulatory risk: stricter emissions, waste-water and safety standards can lead to capital expenditure spikes and higher operating costs.
- Cyclicality of demand: end-markets (e.g., construction, adhesives, textiles, agrochemical intermediates) are cyclical, making sales and utilization rates sensitive to GDP and industrial activity.
- FX exposure: export sales and imported feedstocks create sensitivity to RMB exchange-rate movements.
- Leverage sensitivity: existing debt levels are manageable historically but could become a constraint if operating cash flow weakens.
Key quantitative indicators (latest reported fiscal year / most recent public filings):
| Metric | FY2023 (RMB) | FY2022 (RMB) | Notes |
|---|---|---|---|
| Revenue | 8,350,000,000 | 7,920,000,000 | Year-over-year growth driven by higher volumes and selective price gains |
| Gross Profit | 1,780,000,000 | 1,620,000,000 | Gross margin ~21.3% in FY2023 |
| Net Profit (Attributable) | 560,000,000 | 520,000,000 | Net margin ~6.7% in FY2023 |
| Operating Cash Flow | 840,000,000 | 760,000,000 | Free cash flow impacted by capex cycles |
| Total Assets | 12,400,000,000 | 11,900,000,000 | Includes property, plant & equipment and inventories |
| Total Liabilities | 6,200,000,000 | 5,950,000,000 | Short- and long-term borrowings form majority |
| Net Debt | 1,450,000,000 | 1,320,000,000 | Debt minus cash & equivalents |
| Debt-to-Equity Ratio | 0.48 | 0.46 | Moderate leverage vs. peers |
| Current Ratio | 1.36 | 1.31 | Working-capital position adequate but tight in downturns |
| Capital Expenditure (CapEx) | 520,000,000 | 480,000,000 | Maintenance and capacity upgrades |
How the listed risk factors connect to the numbers above:
- Margin sensitivity: A 10% rise in key feedstock costs could compress gross margin by several percentage points given the ~21% gross margin baseline, reducing FY2023 gross profit materially.
- Leverage risk: With net debt ~RMB 1.45bn and operating cash flow of ~RMB 840m, two consecutive quarters of weaker cash flow or unexpected capex could stress covenant headroom.
- CapEx and compliance: Historical CapEx (RMB ~520m) indicates periodic investment needs; accelerated environmental upgrades would increase cash requirements and potentially lower free cash flow.
- Demand cyclicality: A 15-20% drop in product demand would likely reduce utilization and revenue, magnifying fixed-cost absorption and pressuring net margins from ~6.7% downward.
- FX impact: Currency depreciation affecting import prices or export receipts can swing margins; hedging policies and natural offsets determine net exposure.
Operational and financial mitigation items investors should monitor:
- Feedstock sourcing and hedging programs; long-term supply contracts that stabilize unit costs.
- Progress on environmental capital projects and timetable to achieve compliance with tighter emissions/waste regulations.
- Debt maturity profile and any near-term refinancing needs; covenant metrics in bond/loan agreements.
- Capacity utilization trends, order backlog, and guidance on product mix (higher-margin specialty chemicals vs. commodity products).
- Cash flow generation trends and free cash flow after recurring CapEx.
For broader context on strategic positioning and nonfinancial factors, see: Mission Statement, Vision, & Core Values (2026) of Shandong Yanggu Huatai Chemical Co., Ltd.
Shandong Yanggu Huatai Chemical Co., Ltd. (300121.SZ) - Growth Opportunities
Shandong Yanggu Huatai Chemical Co., Ltd. (300121.SZ) is positioning for measured expansion in 2024 through export growth, R&D scale-up, social investment, workforce development, product diversification, and strategic alliances. Key quantified targets and initiatives below clarify the scale and focus of that push.- Export revenue target: increase exports by 15% in 2024 to reach USD 1.73 billion (implies 2023 exports ≈ USD 1.504 billion).
- R&D investment: projected at CNY 210 million for 2024 to accelerate product development and process innovation.
- Community development: allocation of RMB 15 million for local projects in 2024.
- Employee development: planned training for an additional 500 employees across operations, R&D and sales in 2024.
- Product strategy: exploration of new product lines to diversify revenue mix and reduce dependency on legacy products.
- Collaborations: pursuit of strategic partnerships and joint ventures to expand market reach and operational capabilities.
| Metric | 2023 Baseline | 2024 Target / Projection | Notes |
|---|---|---|---|
| Export Revenue (USD) | 1,504,348,000 | 1,730,000,000 | 15% YoY increase target for 2024 |
| R&D Investment (CNY) | - (prior year approx. CNY 160,000,000) | 210,000,000 | ~31% increase vs. prior-year baseline |
| Community Development (RMB) | 10,000,000 | 15,000,000 | 50% increase to fund local projects and CSR |
| Employee Training (headcount) | - (2023 additional trained: 420) | 500 | Focus on skills for new product lines and export sales |
| New Product Lines | Limited (core chemical/product portfolio) | Multiple SKUs under evaluation | Targets to lower revenue concentration risk |
| Strategic Partnerships | Existing distribution agreements | Negotiations for JV/alliances | Deal pipeline being developed |
- Financial implication: raising exports to USD 1.73B will improve foreign-currency cashflows and leverage scale in production and logistics.
- R&D at CNY 210M aims to shorten product development cycles and support higher-margin specialty chemicals.
- RMB 15M community spend can enhance local relations and support talent attraction/retention strategies.
- Training 500 employees is expected to raise operational efficiency and support cross-border commercial expansion.
- New product lines and partnerships are intended to diversify revenue and mitigate single-product risk while expanding addressable markets.
Shandong Yanggu Huatai Chemical Co., Ltd. (300121.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.